Our vision is to make solutions for genomic tests helping clinicians and diagnostic labs with far-reaching impacts on the current as well as foreseen healthcare challenges. With our high efficacy and shorter turn-around time, we plan to accelerate the biomedical industry.
Diagnostic Solutions
Our AI/ML-driven, high-precision diagnostic solutions provide rapid and reliable confirmation of health conditions. Built to integrate seamlessly into clinical workflows, they deliver accurate results that guide targeted treatments and enable better, data-backed medical decisions.
InheriGene™
Your DNA holds answers. We help you find them.
Advanced genetic diagnostics that moves families from years of uncertainty to a single moment of clarity — before it’s too late to act.
300M+
Over 300 million people worldwide suffer from 7,000 known rare diseases
7 yrs
7 yrs average diagnostic odyssey for rare disease families
1 test
1 test is often all it takes to end the uncertainty
What is InheriGene™
Precision diagnostics. Human-first answers.
InheriGene™ is Genomiki’s advanced genetic diagnostics and reporting platform designed to uncover inherited disorders through deep genomic analysis. It combines phenotype-driven diagnostics with optimized algorithms to deliver clinically actionable answers, not just data. For clinicians, that means faster decisions. For families, it means finally knowing.
The InheriGene™ difference
Most reports tell you what was found. InheriGene™ tells you what it means.
With & Without InheriGene™
With InheriGene™
One clear, actionable answer: Phenotype-driven analysis matches genomic findings to real clinical symptoms. Validated pipelines deliver clinically actionable reports — fast, secure, and built for real decisions.
Without InheriGene™
Years of unanswered questions Fragmented test results. Misdiagnoses. Families passed from specialist to specialist, no closer to understanding what is actually wrong or what comes next.
Why InheriGene™
Built for precision. Designed for people.
- Phenotype-driven diagnostics
Analysis starts with the patient’s clinical picture, not just their sequence — findings are always grounded in real symptoms.
- Optimized genomic algorithms
Faster analysis without compromising depth. Validated interpretation pipelines ensure every result meets clinical-grade accuracy.
- Clinically actionable reports
Not raw data — structured, clear reports that guide diagnosis, treatment planning, and family counselling from day one.
- Secure, anytime access
Patient insights accessible securely from anywhere, so clinicians can act without delay and families stay informed at every step.
- Fast turnaround time
When time matters most, speed is not a luxury, its clinical necessity. InheriGene™ delivers answers when they can still make a difference.
Why InheriGene™
Built for precision. Designed for people.
- Phenotype-driven diagnostics
Analysis starts with the patient’s clinical picture, not just their sequence — findings are always grounded in real symptoms.
- Optimized genomic algorithms
Faster analysis without compromising depth. Validated interpretation pipelines ensure every result meets clinical-grade accuracy.
- Clinically actionable reports
Not raw data — structured, clear reports that guide diagnosis, treatment planning, and family counselling from day one.
- Secure, anytime access
Patient insights accessible securely from anywhere, so clinicians can act without delay and families stay informed at every step.
- Fast turnaround time
When time matters most, speed is not a luxury, its clinical necessity. InheriGene™ delivers answers when they can still make a difference.
Who it's for
For every family still waiting for an answer.
- UNDIAGNOSED SYMPTOMS
Patients with symptoms suggestive of a genetic or metabolic disorder, where conventional testing has not provided clarity.
- HEREDITARY CONDITIONS
Families with known or suspected inherited conditions needing targeted genetic evaluation and risk assessment.
- EARLY DETECTION
Individuals seeking proactive screening for inherited risk, to plan care before symptoms emerge.
- RARE DISEASE PROGRAMS
Clinical genetics teams who need precise, fast, and interpretation-ready genomic reports.
Onquer™
Advanced cancer genomics reporting that transforms tumor data into clinically actionable insights, empowering oncologists, labs, and cancer centers to move with confidence.
- 1 comprehensive report — somatic & germline variants
- HRD scoring for targeted therapy selection
20M+
new cancer diagnoses globally each year
50%+
actionable alterations missed by standard methods
5–10%
of all breast cancers are caused by inherited germline mutations
25–40%
of patients with targetable mutations never receive matched targeted treatment
What is Onquer™
Precision diagnostics. Human-first answers.
Onquer™ is Genomiki’s advanced oncology reporting platform built to transform tumor genomic data into clinically actionable insights. Through expert-curated knowledgebases and validated interpretation pipelines, Onquer bridges the gap between complex sequencing data and confident treatment decisions.
With & Without Onquer™
With Onquer™
Somatic variants detected, interpreted, and linked to targeted therapies and prognostic insights — in one structured, clinically actionable report. Faster decisions. Greater confidence.
Without Onquer™
Complex sequencing output. Fragments of data without clinical context. Oncologists and labs left to interpret variants in isolation with incomplete evidence and no clear therapy link.
Why Onquer™
Built for precision. Designed for oncologists.
- Somatic variant detection
Comprehensive identification of cancer-driving somatic variants alongside clinically relevant germline findings — all in a single analysis run. Covers Single Nucleotide Variants (SNV), Copy Number Variations (CNV), and gene Fusions for complete genomic coverage.
- Hereditary cancer
Comprehensive screening for inherited cancer predisposition variants across high-risk genes — including BRCA1/2, Lynch syndrome genes, and beyond, enabling early intervention, cascade testing, and informed surveillance strategies for patients and families.
- HRD scoring
Homologous Recombination Deficiency scoring to support therapy selection in ovarian, breast, and other solid tumors — directly guiding PARP inhibitor decisions.
- MSI TMB markers
Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) profiling to identify patients most likely to respond to immune checkpoint inhibitors, delivering critical biomarkers for immunotherapy eligibility in a single, streamlined workflow.
- Clinically actionable reports
Structured, oncologist-ready reports — not raw data. Findings are linked to targeted therapies, immunotherapy markers, and prognostic insights from day one.
- Optimized algorithms
Faster genomic analysis without compromising depth or accuracy. Validated pipelines ensure every result meets clinical-grade standards for confident decision-making.
- Expert-curated knowledgebases
Interpretation backed by continuously updated, expert-reviewed cancer knowledgebases — so clinical evidence stays current with evolving oncology science.
Use Cases
For every family still waiting for an answer.
- UNDIAGNOSED SYMPTOMS
Patients with symptoms suggestive of a genetic or metabolic disorder, where conventional testing has not provided clarity.
- HEREDITARY CONDITIONS
Families with known or suspected inherited conditions needing targeted genetic evaluation and risk assessment.
- EARLY DETECTION
Individuals seeking proactive screening for inherited risk, to plan care before symptoms emerge.
- RARE DISEASE PROGRAMS
Clinical genetics teams who need precise, fast, and interpretation-ready genomic reports.